RecruitingNCT03601702

EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke

Multicentric Observational Prospective Study on the Use of the EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke


Sponsor

Niguarda Hospital

Enrollment

100 participants

Start Date

Jan 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Signed Informed Consent Form
  • Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1
  • ASPECTS ≥ 6
  • Mismatch or good collaterals showed at MR or multiphasic CTA or pCT
  • Groin Puncture performed within 12 hours from symptom onset
  • Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment

Exclusion Criteria2

  • Informed consent not given
  • Extracranial or tandem occlusion

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMechanical thrombectomy with EmboTrap ® II Device

Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)


Locations(1)

ASST GOM Niguarda

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03601702


Related Trials